{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:10:23Z","timestamp":1787317823558,"version":"build-2736575974"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Negev Labs"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"DOI":"10.1038\/s41398-025-03428-x","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T14:39:00Z","timestamp":1749825540000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Synergistic behavioral and neuroplastic effects of psilocybin-NMDAR modulator administration"],"prefix":"10.1038","volume":"15","author":[{"given":"Tom","family":"Ben-Tal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilana","family":"Pogodin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Botvinnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzuri","family":"Lifschytz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uriel","family":"Heresco-Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9914-632X","authenticated-orcid":false,"given":"Bernard","family":"Lerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,13]]},"reference":[{"key":"3428_CR1","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1001\/jamapsychiatry.2020.2171","volume":"78","author":"D Nutt","year":"2021","unstructured":"Nutt D, Carhart-Harris R. The current status of psychedelics in psychiatry. JAMA Psychiatry. 2021;78:121\u20132.","journal-title":"JAMA Psychiatry"},{"key":"3428_CR2","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.3390\/molecules27082520","volume":"27","author":"H Lowe","year":"2022","unstructured":"Lowe H, Toyang N, Steele B, Grant J, Ali A, Gordon L, et al. Psychedelics: alternative and potential therapeutic options for treating mood and anxiety disorders. Molecules. 2022;27:2520.","journal-title":"Molecules"},{"key":"3428_CR3","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41380-022-01832-z","volume":"28","author":"G Wolf","year":"2023","unstructured":"Wolf G, Singh S, Blakolmer K, Lerer L, Lifschytz T, Heresco-Levy U, et al. Could psychedelic drugs have a role in the treatment of schizophrenia? Rationale and strategy for safe implementation. Mol Psychiatry. 2023;28:44\u201358.","journal-title":"Mol Psychiatry"},{"key":"3428_CR4","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","volume":"23","author":"C Ly","year":"2018","unstructured":"Ly C, Greb AC, Cameron LP, Wong JM, Barragan EV, Wilson PC, et al. Psychedelics promote structural and functional neural plasticity. Cell Rep. 2018;23:3170\u201382.","journal-title":"Cell Rep"},{"key":"3428_CR5","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1038\/s41593-023-01316-5","volume":"26","author":"R Moliner","year":"2023","unstructured":"Moliner R, Girych M, Brunello CA, Kovaleva V, Biojone C, Enkavi G, et al. Psychedelics promote plasticity by directly binding to BDNF receptor TrkB. Nat Neurosci. 2023;26:1032\u201341.","journal-title":"Nat Neurosci"},{"key":"3428_CR6","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1016\/j.neuron.2021.06.008","volume":"109","author":"L-X Shao","year":"2021","unstructured":"Shao L-X, Liao C, Gregg I, Davoudian PA, Savalia NK, Delagarza K, et al. Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron. 2021;109:2535\u201344.e2534.","journal-title":"Neuron"},{"key":"3428_CR7","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41386-022-01389-z","volume":"48","author":"AE Calder","year":"2023","unstructured":"Calder AE, Hasler G. Towards an understanding of psychedelic-induced neuroplasticity. Neuropsychopharmacology. 2023;48:104\u201312.","journal-title":"Neuropsychopharmacology"},{"key":"3428_CR8","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1021\/acsptsci.0c00194","volume":"4","author":"DB Yaden","year":"2021","unstructured":"Yaden DB, Griffiths RR. The subjective effects of psychedelics are necessary for their enduring therapeutic effects. ACS Pharmacol Transl Sci. 2021;4:568\u201372.","journal-title":"ACS Pharmacol Transl Sci"},{"key":"3428_CR9","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1021\/acsptsci.0c00192","volume":"4","author":"DE Olson","year":"2021","unstructured":"Olson DE. The subjective effects of psychedelics may not be necessary for their enduring therapeutic effects. ACS Pharmacol Transl Sci. 2021;4:563\u20137.","journal-title":"ACS Pharmacol Transl Sci"},{"key":"3428_CR10","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1001\/jamapsychiatry.2024.2546","volume":"81","author":"JT Hinkle","year":"2024","unstructured":"Hinkle JT, Graziosi M, Nayak SM, Yaden DB. Adverse events in studies of classic psychedelics: A systematic review and meta-analysis. JAMA Psychiatry. 2024;81:1225\u201335.","journal-title":"JAMA Psychiatry"},{"key":"3428_CR11","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41380-023-02312-8","volume":"29","author":"U Heresco-Levy","year":"2024","unstructured":"Heresco-Levy U, Lerer B. Synergistic psychedelic-NMDAR modulator treatment for neuropsychiatric disorders. Mol Psychiatry. 2024;29:146\u201352.","journal-title":"Mol Psychiatry"},{"key":"3428_CR12","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.conb.2012.01.007","volume":"22","author":"DL Hunt","year":"2012","unstructured":"Hunt DL, Castillo PE. Synaptic plasticity of NMDA receptors: mechanisms and functional implications. Curr Opin Neurobiol. 2012;22:496\u2013508.","journal-title":"Curr Opin Neurobiol"},{"key":"3428_CR13","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1007\/s00213-014-3738-4","volume":"232","author":"P Popik","year":"2015","unstructured":"Popik P, Holuj M, Nikiforuk A, Kos T, Trullas R, Skolnick P. 1-Aminocyclopropanecarboxylic acid (ACPC) produces procognitive but not antipsychotic-like effects in rats. Psychopharmacology (Berl). 2015;232:1025\u201338.","journal-title":"Psychopharmacology (Berl)"},{"key":"3428_CR14","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s00406-013-0399-y","volume":"263","author":"K Hashimoto","year":"2013","unstructured":"Hashimoto K, Malchow B, Falkai P, Schmitt A. Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur Arch Psychiatry Clin Neurosci. 2013;263:367\u201377.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"3428_CR15","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3389\/fnmol.2016.00169","volume":"9","author":"SY Chan","year":"2017","unstructured":"Chan SY, Matthews E, Burnet PW. ON or OFF?: modulating the N-methyl-D-aspartate receptor in major depression. Front Mol Neurosci. 2017;9:169.","journal-title":"Front Mol Neurosci"},{"key":"3428_CR16","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/bs.pbr.2018.07.008","volume":"242","author":"D De Gregorio","year":"2018","unstructured":"De Gregorio D, Enns JP, Nu\u00f1ez NA, Posa L, Gobbi G. d-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: mechanism of action and potential therapeutic applications in mood disorders. Prog Brain Res. 2018;242:69\u201396.","journal-title":"Prog Brain Res"},{"key":"3428_CR17","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.tips.2021.08.003","volume":"42","author":"LR Aleksandrova","year":"2021","unstructured":"Aleksandrova LR, Phillips AG. Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics. Trends Pharmacol Sci. 2021;42:929\u201342.","journal-title":"Trends Pharmacol Sci"},{"key":"3428_CR18","doi-asserted-by":"publisher","first-page":"e2022489118","DOI":"10.1073\/pnas.2022489118","volume":"118","author":"N Hesselgrave","year":"2021","unstructured":"Hesselgrave N, Troppoli TA, Wulff AB, Cole AB, Thompson SM. Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice. Proc Natl Acad Sci USA. 2021;118:e2022489118.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3428_CR19","doi-asserted-by":"publisher","first-page":"307106","DOI":"10.1155\/2014\/307106","volume":"2014","author":"B Rolland","year":"2014","unstructured":"Rolland B, Jardri R, Amad A, Thomas P, Cottencin O, Bordet R. Pharmacology of hallucinations: several mechanisms for one single symptom? Biomed Res Int. 2014;2014:307106.","journal-title":"Biomed Res Int"},{"key":"3428_CR20","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/00008877-199902000-00006","volume":"10","author":"R Dall\u2019Olio","year":"1999","unstructured":"Dall\u2019Olio R, Gaggi R, Bonfante V, Gandolfi O. The non-competitive NMDA receptor blocker dizocilpine potentiates serotonergic function. Behav Pharmacol. 1999;10:63\u201371.","journal-title":"Behav Pharmacol"},{"key":"3428_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-022-01930-0","volume":"12","author":"K Nakao","year":"2022","unstructured":"Nakao K, Singh M, Sapkota K, Fitzgerald A, Hablitz JJ, Nakazawa K. 5-HT2A receptor dysregulation in a schizophrenia relevant mouse model of NMDA receptor hypofunction. Transl Psychiatry. 2022;12:168.","journal-title":"Transl Psychiatry"},{"key":"3428_CR22","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1097\/00008877-200011000-00010","volume":"11","author":"R Dall\u2019Olio","year":"2000","unstructured":"Dall\u2019Olio R, Gandolfi O, Gaggi R. D-cycloserine, a positive modulator of NMDA receptors, inhibits serotonergic function. Behav Pharmacol. 2000;11:631\u20137.","journal-title":"Behav Pharmacol"},{"key":"3428_CR23","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/nrn2884","volume":"11","author":"FX Vollenweider","year":"2010","unstructured":"Vollenweider FX, Kometer M. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci. 2010;11:642\u201351.","journal-title":"Nat Rev Neurosci"},{"key":"3428_CR24","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00221-013-3579-0","volume":"228","author":"BJ Catlow","year":"2013","unstructured":"Catlow BJ, Song S, Paredes DA, Kirstein CL, Sanchez-Ramos J. Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning. Exp Brain Res. 2013;228:481\u201391.","journal-title":"Exp Brain Res"},{"key":"3428_CR25","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","volume":"384","author":"R Carhart-Harris","year":"2021","unstructured":"Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, et al. Trial of psilocybin versus escitalopram for depression. N Engl J Med. 2021;384:1402\u201311.","journal-title":"N Engl J Med"},{"key":"3428_CR26","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","volume":"387","author":"GM Goodwin","year":"2022","unstructured":"Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med. 2022;387:1637\u201348.","journal-title":"N Engl J Med"},{"key":"3428_CR27","doi-asserted-by":"publisher","first-page":"100906","DOI":"10.1016\/j.xcrm.2022.100906","volume":"4","author":"JJ Mann","year":"2023","unstructured":"Mann JJ. Is psilocybin an effective antidepressant and what is its mechanism of action? Cell Rep Med. 2023;4:100906.","journal-title":"Cell Rep Med"},{"key":"3428_CR28","doi-asserted-by":"publisher","first-page":"4926","DOI":"10.1073\/pnas.97.9.4926","volume":"97","author":"J-P Mothet","year":"2000","unstructured":"Mothet J-P, Parent AT, Wolosker H, Brady RO Jr, Linden DJ, Ferris CD, et al. D-serine is an endogenous ligand for the glycine site of the N-methyl-D-aspartate receptor. Proc Natl Acad Sci USA. 2000;97:4926\u201331.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3428_CR29","doi-asserted-by":"publisher","first-page":"10792","DOI":"10.1021\/acs.jafc.7b04217","volume":"65","author":"I-H Wei","year":"2017","unstructured":"Wei I-H, Chen K-T, Tsai M-H, Wu C-H, Lane H-Y, Huang C-C. Acute amino acid D-serine administration, similar to ketamine, produces antidepressant-like effects through identical mechanisms. J Agric Food Chem. 2017;65:10792\u2013803.","journal-title":"J Agric Food Chem"},{"key":"3428_CR30","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1017\/S1461145711001386","volume":"15","author":"O Malkesman","year":"2012","unstructured":"Malkesman O, Austin DR, Tragon T, Wang G, Rompala G, Hamidi AB, et al. Acute D-serine treatment produces antidepressant-like effects in rodents. Int J Neuropsychopharmacol. 2012;15:1135\u201348.","journal-title":"Int J Neuropsychopharmacol"},{"key":"3428_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-020-00870-x","volume":"10","author":"H Wolosker","year":"2020","unstructured":"Wolosker H, Balu DT. D-Serine as the gatekeeper of NMDA receptor activity: implications for the pharmacologic management of anxiety disorders. Transl Psychiatry. 2020;10:184.","journal-title":"Transl Psychiatry"},{"key":"3428_CR32","doi-asserted-by":"publisher","first-page":"754032","DOI":"10.3389\/fpsyt.2021.754032","volume":"12","author":"M Orzylowski","year":"2021","unstructured":"Orzylowski M, Fujiwara E, Mousseau DD, Baker GB. An overview of the involvement of d-serine in cognitive impairment in normal aging and dementia. Front Psychiatry. 2021;12:754032.","journal-title":"Front Psychiatry"},{"key":"3428_CR33","first-page":"155","volume":"7","author":"S Sultan","year":"2013","unstructured":"Sultan S, Gebara EG, Moullec K, Toni N. D-serine increases adult hippocampal neurogenesis. Front Neurosci. 2013;7:155.","journal-title":"Front Neurosci"},{"key":"3428_CR34","doi-asserted-by":"publisher","first-page":"859","DOI":"10.2165\/11586650-000000000-00000","volume":"25","author":"SP Singh","year":"2011","unstructured":"Singh SP, Singh V. Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia. CNS Drugs. 2011;25:859\u201385.","journal-title":"CNS Drugs"},{"key":"3428_CR35","doi-asserted-by":"publisher","first-page":"522","DOI":"10.2174\/138161210790361452","volume":"16","author":"GE Tsai","year":"2010","unstructured":"Tsai GE, Lin P-Y. Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. Curr Pharm Des. 2010;16:522\u201337.","journal-title":"Curr Pharm Des"},{"key":"3428_CR36","doi-asserted-by":"publisher","first-page":"pyv102","DOI":"10.1093\/ijnp\/pyv102","volume":"19","author":"S Schade","year":"2016","unstructured":"Schade S, Paulus W. D-cycloserine in neuropsychiatric diseases: a systematic review. Int J Neuropsychopharmacol. 2016;19:pyv102.","journal-title":"Int J Neuropsychopharmacol"},{"key":"3428_CR37","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1096\/fj.06-7856com","volume":"21","author":"R Yaka","year":"2007","unstructured":"Yaka R, Biegon A, Grigoriadis N, Simeonidou C, Grigoriadis S, Alexandrovich AG, et al. D\u2010cycloserine improves functional recovery and reinstates long\u2010term potentiation (LTP) in a mouse model of closed head injury. FASEB J. 2007;21:2033\u201341.","journal-title":"FASEB J"},{"key":"3428_CR38","doi-asserted-by":"publisher","first-page":"e0183026","DOI":"10.1371\/journal.pone.0183026","volume":"12","author":"ES Na","year":"2017","unstructured":"Na ES, De Jes\u00fas-Cort\u00e9s H, Martinez-Rivera A, Kabir ZD, Wang J, Ramesh V, et al. D-cycloserine improves synaptic transmission in an animal mode of rett syndrome. PLoS ONE. 2017;12:e0183026.","journal-title":"PLoS ONE"},{"key":"3428_CR39","doi-asserted-by":"publisher","first-page":"4811","DOI":"10.1007\/s12035-017-0685-1","volume":"55","author":"H-F Wu","year":"2018","unstructured":"Wu H-F, Chen PS, Hsu Y-T, Lee C-W, Wang T-F, Chen Y-J, et al. D-cycloserine ameliorates autism-like deficits by removing GluA2-containing AMPA receptors in a valproic acid-induced rat model. Mol Neurobiol. 2018;55:4811\u201324.","journal-title":"Mol Neurobiol"},{"key":"3428_CR40","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1523\/JNEUROSCI.22-06-02343.2002","volume":"22","author":"DL Walker","year":"2002","unstructured":"Walker DL, Ressler KJ, Lu K-T, Davis M. Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats. J Neurosci. 2002;22:2343\u201351.","journal-title":"J Neurosci"},{"key":"3428_CR41","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/cercor\/bhn099","volume":"19","author":"F Sotres-Bayon","year":"2009","unstructured":"Sotres-Bayon F, Diaz-Mataix L, Bush DE, LeDoux JE. Dissociable roles for the ventromedial prefrontal cortex and amygdala in fear extinction: NR2B contribution. Cereb Cortex. 2009;19:474\u201382.","journal-title":"Cereb Cortex"},{"key":"3428_CR42","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1038\/sj.npp.1301605","volume":"33","author":"S Yamamoto","year":"2008","unstructured":"Yamamoto S, Morinobu S, Fuchikami M, Kurata A, Kozuru T, Yamawaki S. Effects of single prolonged stress and D-cycloserine on contextual fear extinction and hippocampal NMDA receptor expression in a rat model of PTSD. Neuropsychopharmacology. 2008;33:2108\u201316.","journal-title":"Neuropsychopharmacology"},{"key":"3428_CR43","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.physbeh.2007.08.020","volume":"93","author":"AJ Silvestri","year":"2008","unstructured":"Silvestri AJ, Root DH. Effects of REM deprivation and an NMDA agonist on the extinction of conditioned fear. Physiol Behav. 2008;93:274\u201381.","journal-title":"Physiol Behav"},{"key":"3428_CR44","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.neuroscience.2006.07.013","volume":"142","author":"M Bertotto","year":"2006","unstructured":"Bertotto M, Bustos S, Molina V, Martijena I. Influence of ethanol withdrawal on fear memory: effect of D-cycloserine. Neuroscience. 2006;142:979\u201390.","journal-title":"Neuroscience"},{"key":"3428_CR45","doi-asserted-by":"publisher","first-page":"4056","DOI":"10.1523\/JNEUROSCI.5539-08.2009","volume":"29","author":"H Yu","year":"2009","unstructured":"Yu H, Wang Y, Pattwell S, Jing D, Liu T, Zhang Y, et al. Variant BDNF Val66Met polymorphism affects extinction of conditioned aversive memory. J Neurosci. 2009;29:4056\u201364.","journal-title":"J Neurosci"},{"key":"3428_CR46","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.biopsych.2008.01.012","volume":"63","author":"MM Norberg","year":"2008","unstructured":"Norberg MM, Krystal JH, Tolin DF. A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biol Psychiatry. 2008;63:1118\u201326.","journal-title":"Biol Psychiatry"},{"key":"3428_CR47","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1017\/S1461145712000910","volume":"16","author":"U Heresco-Levy","year":"2013","unstructured":"Heresco-Levy U, Gelfin G, Bloch B, Levin R, Edelman S, Javitt DC, et al. A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression. Int J Neuropsychopharmacol. 2013;16:501\u20136.","journal-title":"Int J Neuropsychopharmacol"},{"key":"3428_CR48","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1038\/s41386-019-0480-y","volume":"44","author":"M-H Chen","year":"2019","unstructured":"Chen M-H, Cheng C-M, Gueorguieva R, Lin W-C, Li C-T, Hong C-J, et al. Maintenance of antidepressant and antisuicidal effects by D-cycloserine among patients with treatment-resistant depression who responded to low-dose ketamine infusion: a double-blind randomized placebo\u2013control study. Neuropsychopharmacology. 2019;44:2112\u20138.","journal-title":"Neuropsychopharmacology"},{"key":"3428_CR49","doi-asserted-by":"publisher","first-page":"19629","DOI":"10.4088\/JCP.14l09527","volume":"76","author":"JT Kantrowitz","year":"2015","unstructured":"Kantrowitz JT, Halberstam B, Gangwisch J. Single-dose ketamine followed by daily< span Style=. J Clin Psychiatry. 2015;76:19629.","journal-title":"J Clin Psychiatry"},{"key":"3428_CR50","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1002\/dta.1333","volume":"4","author":"CE Canal","year":"2012","unstructured":"Canal CE, Morgan D. Head\u2010twitch response in rodents induced by the hallucinogen 2, 5\u2010dimethoxy\u20104\u2010iodoamphetamine: a comprehensive history, a re\u2010evaluation of mechanisms, and its utility as a model. Drug Test Anal. 2012;4:556\u201376.","journal-title":"Drug Test Anal"},{"key":"3428_CR51","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.neuropharm.2011.01.017","volume":"61","author":"AL Halberstadt","year":"2011","unstructured":"Halberstadt AL, Geyer MA. Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology. 2011;61:364\u201381.","journal-title":"Neuropharmacology"},{"key":"3428_CR52","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s00213-013-3006-z","volume":"227","author":"AL Halberstadt","year":"2013","unstructured":"Halberstadt AL, Geyer MA. Characterization of the head-twitch response induced by hallucinogens in mice: detection of the behavior based on the dynamics of head movement. Psychopharmacology (Berl). 2013;227:727\u201339.","journal-title":"Psychopharmacology (Berl)"},{"key":"3428_CR53","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.neuroscience.2014.08.047","volume":"280","author":"T Hiyoshi","year":"2014","unstructured":"Hiyoshi T, Kambe D, Karasawa J, Chaki S. Involvement of glutamatergic and GABAergic transmission in MK-801-increased gamma band oscillation power in rat cortical electroencephalograms. Neuroscience. 2014;280:262\u201374.","journal-title":"Neuroscience"},{"key":"3428_CR54","first-page":"75","volume":"9","author":"J Svoboda","year":"2015","unstructured":"Svoboda J, Stankova A, Entlerova M, Stuchlik A. Acute administration of MK-801 in an animal model of psychosis in rats interferes with cognitively demanding forms of behavioral flexibility on a rotating arena. Front Behav Neurosci. 2015;9:75.","journal-title":"Front Behav Neurosci"},{"key":"3428_CR55","doi-asserted-by":"publisher","first-page":"14148","DOI":"10.3390\/ijms232214148","volume":"23","author":"O Shahar","year":"2022","unstructured":"Shahar O, Botvinnik A, Esh-Zuntz N, Brownstien M, Wolf R, Lotan A, et al. Role of 5-HT2A, 5-HT2C, 5-HT1A and TAAR1 receptors in the head twitch response induced by 5-hydroxytryptophan and psilocybin: translational implications. Int J Mol Sci. 2022;23:14148.","journal-title":"Int J Mol Sci"},{"key":"3428_CR56","doi-asserted-by":"publisher","first-page":"107933","DOI":"10.1016\/j.neuropharm.2019.107933","volume":"167","author":"AL Halberstadt","year":"2020","unstructured":"Halberstadt AL, Chatha M, Klein AK, Wallach J, Brandt SD. Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species. Neuropharmacology. 2020;167:107933.","journal-title":"Neuropharmacology"},{"key":"3428_CR57","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/0304-3940(87)90425-3","volume":"76","author":"T Nabeshima","year":"1987","unstructured":"Nabeshima T, Ishikawa K, Yamaguchi K, Furukawa H, Kameyama T. Phencyclidine-induced head-twitch responses as 5-HT2 receptor-mediated behavior in rats. Neurosci Lett. 1987;76:335\u20138.","journal-title":"Neurosci Lett"},{"key":"3428_CR58","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1016\/S0024-3205(98)00519-0","volume":"63","author":"H-S Kim","year":"1998","unstructured":"Kim H-S, Park I-S, Park W-K. NMDA receptor antagonists enhance 5-HT2 receptor-mediated behavior, head-twitch response, in mice. Life Sci. 1998;63:2305\u201311.","journal-title":"Life Sci"},{"key":"3428_CR59","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.neuint.2007.06.003","volume":"51","author":"T Fujihira","year":"2007","unstructured":"Fujihira T, Kanematsu S, Umino A, Yamamoto N, Nishikawa T. Selective increase in the extracellular D-serine contents by D-cycloserine in the rat medial frontal cortex. Neurochem Int. 2007;51:233\u20136.","journal-title":"Neurochem Int"},{"key":"3428_CR60","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1176\/appi.ajp.20231063","volume":"182","author":"ST Aaronson","year":"2025","unstructured":"Aaronson ST, van der Vaart A, Miller T, LaPratt J, Swartz K, Shoultz A, et al. Single-dose psilocybin for depression with severe treatment resistance: an open-label trial. Am J Psychiatry. 2025;182:104\u201313.","journal-title":"Am J Psychiatry"},{"key":"3428_CR61","doi-asserted-by":"publisher","first-page":"974","DOI":"10.3389\/fphar.2017.00974","volume":"8","author":"L Roseman","year":"2017","unstructured":"Roseman L, Nutt DJ, Carhart-Harris RL. Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Front Pharmacol. 2017;8:974.","journal-title":"Front Pharmacol"},{"key":"3428_CR62","doi-asserted-by":"publisher","unstructured":"Hashimoto K Are \u201cmystical experiences\u201d essential for antidepressant actions of ketamine and the classic psychedelics? Eur Arch Psychiatry Clin Neurosci 2024: 1-14. https:\/\/doi.org\/10.1007\/s00406-024-01770-7.","DOI":"10.1007\/s00406-024-01770-7"},{"key":"3428_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-023-02456-9","volume":"13","author":"S Singh","year":"2023","unstructured":"Singh S, Botvinnik A, Shahar O, Wolf G, Yakobi C, Saban M, et al. Effect of psilocybin on marble burying in ICR mice: role of 5-HT1A receptors and implications for the treatment of obsessive-compulsive disorder. Transl Psychiatry. 2023;13:164.","journal-title":"Transl Psychiatry"},{"key":"3428_CR64","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/s41386-024-01794-6","volume":"49","author":"M Sekssaoui","year":"2024","unstructured":"Sekssaoui M, Bockaert J, Marin P, B\u00e9camel C. Antidepressant-like effects of psychedelics in a chronic despair mouse model: is the 5-HT2A receptor the unique player? Neuropsychopharmacology. 2024;49:747\u201356.","journal-title":"Neuropsychopharmacology"},{"key":"3428_CR65","doi-asserted-by":"publisher","first-page":"102799","DOI":"10.1016\/j.eclinm.2024.102799","volume":"76","author":"D Erritzoe","year":"2024","unstructured":"Erritzoe D, Barba T, Greenway KT, Murphy R, Martell J, Giribaldi B, et al. Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial. EClinicalMedicine. 2024;76:102799.","journal-title":"EClinicalMedicine"},{"key":"3428_CR66","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S0014-2999(97)01188-6","volume":"335","author":"P Martin","year":"1997","unstructured":"Martin P, Waters NR, Waters SE, Carlsson A, Carlsson ML. MK-801-induced hyperlocomotion: differential effects of M100907, SDZ PSD 958 and raclopride. Eur J Pharmacol. 1997;335:107\u201316.","journal-title":"Eur J Pharmacol"},{"key":"3428_CR67","first-page":"43","volume":"7","author":"L Bender","year":"1966","unstructured":"Bender L. D-lysergic acid in the treatment of the biological features of childhood schizophrenia. Dis Nerv Syst. 1966;7:43\u201346.","journal-title":"Dis Nerv Syst"},{"key":"3428_CR68","first-page":"44","volume":"1","author":"RE Mogar","year":"1969","unstructured":"Mogar RE, Aldrich RW. The use of psychedelic agents with autistic schizophrenic children. Behav Neuropsychiatry. 1969;1:44\u201350.","journal-title":"Behav Neuropsychiatry"},{"key":"3428_CR69","first-page":"97","volume":"14","author":"R Shirvaikar","year":"1966","unstructured":"Shirvaikar R, Kelkar Y. Therapeutic trial of lysergic acid diethylamide (LSD) and thioridazine in chronic schizophrenia. Neurol India. 1966;14:97\u2013101.","journal-title":"Neurol India"},{"key":"3428_CR70","doi-asserted-by":"publisher","first-page":"E6983","DOI":"10.1073\/pnas.1517045112","volume":"112","author":"X Chen","year":"2015","unstructured":"Chen X, Levy JM, Hou A, Winters C, Azzam R, Sousa AA, et al. PSD-95 family MAGUKs are essential for anchoring AMPA and NMDA receptor complexes at the postsynaptic density. Proc Natl Acad Sci USA. 2015;112:E6983\u2013E6992.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3428_CR71","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1126\/science.7569905","volume":"269","author":"H-C Kornau","year":"1995","unstructured":"Kornau H-C, Schenker LT, Kennedy MB, Seeburg PH. Domain interaction between NMDA receptor subunits and the postsynaptic density protein PSD-95. Science. 1995;269:1737\u201340.","journal-title":"Science"},{"key":"3428_CR72","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.pnpbp.2017.11.016","volume":"82","author":"AA Coley","year":"2018","unstructured":"Coley AA, Gao W-J. PSD95: A synaptic protein implicated in schizophrenia or autism? Prog Neuropsychopharmacol Biol Psychiatry. 2018;82:187\u201394.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"3428_CR73","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.jpba.2018.09.026","volume":"162","author":"H Hasegawa","year":"2019","unstructured":"Hasegawa H, Masuda N, Natori H, Shinohara Y, Ichida K. Pharmacokinetics and toxicokinetics of d-serine in rats. J Pharm Biomed Anal. 2019;162:264\u201371.","journal-title":"J Pharm Biomed Anal"},{"key":"3428_CR74","doi-asserted-by":"publisher","first-page":"726365","DOI":"10.3389\/fpsyt.2021.726365","volume":"12","author":"A Meftah","year":"2021","unstructured":"Meftah A, Hasegawa H, Kantrowitz JT. D-Serine: a cross species review of safety. Front Psychiatry. 2021;12:726365.","journal-title":"Front Psychiatry"},{"key":"3428_CR75","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.schres.2010.05.012","volume":"121","author":"JT Kantrowitz","year":"2010","unstructured":"Kantrowitz JT, Malhotra AK, Cornblatt B, Silipo G, Balla A, Suckow RF, et al. High dose D-serine in the treatment of schizophrenia. Schizophr Res. 2010;121:125\u201330.","journal-title":"Schizophr Res"},{"key":"3428_CR76","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1113\/JP280875","volume":"600","author":"C Geoffroy","year":"2022","unstructured":"Geoffroy C, Paoletti P, Mony L. Positive allosteric modulation of NMDA receptors: mechanisms, physiological impact and therapeutic potential. J Physiol. 2022;600:233\u201359.","journal-title":"J Physiol"},{"key":"3428_CR77","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.biopsych.2009.01.002","volume":"65","author":"K Hashimoto","year":"2009","unstructured":"Hashimoto K, Fujita Y, Horio M, Kunitachi S, Iyo M, Ferraris D, et al. Co-administration of a D-amino acid oxidase inhibitor potentiates the efficacy of D-serine in attenuating prepulse inhibition deficits after administration of dizocilpine. Biol Psychiatry. 2009;65:1103\u20136.","journal-title":"Biol Psychiatry"},{"key":"3428_CR78","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.2174\/1381612811319140002","volume":"19","author":"S Sacchi","year":"2013","unstructured":"Sacchi S, Rosini E, Pollegioni L, Molla G. D-amino acid oxidase inhibitors as a novel class of drugs for schizophrenia therapy. Curr Pharm Des. 2013;19:2499\u2013511.","journal-title":"Curr Pharm Des"},{"key":"3428_CR79","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S0031-6997(24)01382-6","volume":"50","author":"W Danysz","year":"1998","unstructured":"Danysz W, Parsons CG. Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications. Pharmacol Rev. 1998;50:597\u2013664.","journal-title":"Pharmacol Rev"},{"key":"3428_CR80","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S0028-3908(01)00073-9","volume":"41","author":"A Sheinin","year":"2001","unstructured":"Sheinin A, Shavit S, Benveniste M. Subunit specificity and mechanism of action of NMDA partial agonist D-cycloserine. Neuropharmacology. 2001;41:151\u20138.","journal-title":"Neuropharmacology"},{"key":"3428_CR81","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1093\/schbul\/sbs012","volume":"38","author":"DC Goff","year":"2012","unstructured":"Goff DC. D-cycloserine: an evolving role in learning and neuroplasticity in schizophrenia. Schizophr Bull. 2012;38:936\u201341.","journal-title":"Schizophr Bull"},{"key":"3428_CR82","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/bs.apha.2016.02.001","volume":"76","author":"D Goff","year":"2016","unstructured":"Goff D. The therapeutic role of d-cycloserine in schizophrenia. Adv Pharmacol. 2016;76:39\u201366.","journal-title":"Adv Pharmacol"},{"key":"3428_CR83","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2174\/1570159X14666160225154812","volume":"15","author":"DC Goff","year":"2017","unstructured":"Goff DC. D-cycloserine in schizophrenia: new strategies for improving clinical outcomes by enhancing plasticity. Curr Neuropharmacol. 2017;15:21\u201334.","journal-title":"Curr Neuropharmacol"},{"key":"3428_CR84","doi-asserted-by":"publisher","first-page":"pyv128","DOI":"10.1093\/ijnp\/pyv128","volume":"19","author":"SB Sartori","year":"2016","unstructured":"Sartori SB, Maurer V, Murphy C, Schmuckermair C, Muigg P, Neumann ID, et al. Combined neuropeptide S and D-cycloserine augmentation prevents the return of fear in extinction-impaired rodents: advantage of dual versus single drug approaches. Int J Neuropsychopharmacol. 2016;19:pyv128.","journal-title":"Int J Neuropsychopharmacol"},{"key":"3428_CR85","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1001\/jamapsychiatry.2022.3255","volume":"79","author":"J Cole","year":"2022","unstructured":"Cole J, Sohn MN, Harris AD, Bray SL, Patten SB, McGirr A. Efficacy of adjunctive D-cycloserine to intermittent theta-burst stimulation for major depressive disorder: a randomized clinical trial. JAMA Psychiatry. 2022;79:1153\u201361.","journal-title":"JAMA Psychiatry"},{"key":"3428_CR86","doi-asserted-by":"publisher","first-page":"173586","DOI":"10.1016\/j.pbb.2023.173586","volume":"227","author":"MT Sapko","year":"2023","unstructured":"Sapko MT, Hanania T, Chang Q, Javitt JC. D-cycloserine is not susceptible to self-administration using an intravenous self-administration model in male ketamine-habituated Sprague-Dawley rats. Pharmacol Biochem Behav. 2023;227:173586.","journal-title":"Pharmacol Biochem Behav"},{"key":"3428_CR87","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1177\/10915818231176971","volume":"42","author":"W Jordan","year":"2023","unstructured":"Jordan W, Sapko MT, Siegel R, Javitt J. NRX-101, a rapid-acting anti-depressant, does not cause neurotoxicity following ketamine administration in preclinical models. Int J Toxicol. 2023;42:379\u201385.","journal-title":"Int J Toxicol"},{"key":"3428_CR88","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1128\/am.21.5.888-892.1971","volume":"21","author":"HL David","year":"1971","unstructured":"David HL. Resistance to D-cycloserine in the tubercle bacilli: mutation rate and transport of alanine in parental cells and drug-resistant mutants. Appl Microbiol. 1971;21:888\u201392.","journal-title":"Appl Microbiol"},{"key":"3428_CR89","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1080\/13813455.2019.1687523","volume":"128","author":"P Janhavi","year":"2022","unstructured":"Janhavi P, Divyashree S, Sanjailal KP, Muthukumar SP. DoseCal: a virtual calculator for dosage conversion between human and different animal species. Arch Physiol Biochem. 2022;128:426\u201330.","journal-title":"Arch Physiol Biochem"},{"key":"3428_CR90","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1378\/chest.29.3.241","volume":"29","author":"IG Epstein","year":"1956","unstructured":"Epstein IG, Nair KG, Boyd LJ. The treatment of human pulmonary tuberculosis with cycloserine: progress report. Dis Chest. 1956;29:241\u201357.","journal-title":"Dis Chest"},{"key":"3428_CR91","doi-asserted-by":"publisher","first-page":"S308","DOI":"10.1093\/cid\/ciy624","volume":"67","author":"D Deshpande","year":"2018","unstructured":"Deshpande D, Alffenaar JC, K\u00f6ser CU, Dheda K, Chapagain ML, Simbar N, et al. d-cycloserine pharmacokinetics\/pharmacodynamics, susceptibility, and dosing implications in multidrug-resistant tuberculosis: a faustian deal. Clin Infect Dis. 2018;67:S308\u2013s316.","journal-title":"Clin Infect Dis"},{"key":"3428_CR92","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1523\/JNEUROSCI.1316-22.2022","volume":"43","author":"P Zanos","year":"2023","unstructured":"Zanos P, Brown KA, Georgiou P, Yuan P, Zarate CA Jr., Thompson SM, et al. NMDA receptor activation-dependent antidepressant-relevant behavioral and synaptic actions of ketamine. J Neurosci. 2023;43:1038\u201350.","journal-title":"J Neurosci"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-025-03428-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-025-03428-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-025-03428-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T17:01:39Z","timestamp":1749834099000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-025-03428-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,13]]},"references-count":92,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3428"],"URL":"https:\/\/doi.org\/10.1038\/s41398-025-03428-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.11.28.625811","asserted-by":"object"}]},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,13]]},"assertion":[{"value":"16 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PCT WO 2024\/052895 A1 (Inventors: BL, UHL), submitted by Hadasit Medical Research and Development Ltd and Ezrath Nashim - the Rabanit Herzog Memorial Hospital discloses SP-NMDAR modulator combination therapy for psychiatric and other disorders.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Experiments were approved by the Authority for Biological and Biomedical Models, Hebrew University of Jerusalem, Israel (Animal Care and Use Committee Approval Numbers: MD-22-17000-4 and MD-24-17494-4). All methods were performed in accordance with the relevant guidelines and regulations and all efforts were made to minimize animal suffering and the number of animals used.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"200"}}